RecovryAI Exits Stealth With FDA Breakthrough Status for Surgical Recovery Chatbot

RecovryAI, a startup building a generative AI assistant for patients recovering from surgery at home, said on March 3 that the U.S. Food and Drug Administration has granted breakthrough device designation to its Virtual Care Assistants, Medical Economics reported. The company announced the designation as it came out of stealth.

Breakthrough device designation gives a developer more frequent interaction with FDA reviewers during development. It is not a clearance or approval, and the product cannot be marketed as a medical device until the FDA authorizes it.

According to STAT, the FDA granted the designation in November, without public notice, to a large language model-powered chatbot for patients recovering from joint replacement surgery. STAT reported that the agency has yet to authorize any device that relies on generative AI, which makes the designation an early signal of how the FDA may approach patient-facing chatbots that fall under its oversight.

What the software is meant to do

STAT reported that the device would be prescribed to patients for the 30 days after surgery. It would prompt them to check in twice a day about sleep, activity, diet and other parts of their recovery, answer their questions, and escalate to a care team when needed.

Medical Economics, citing the company, described the Virtual Care Assistants as physician-prescribed AI systems that give recovery guidance based on clinical protocols and alert care teams when a patient appears to be deviating from an expected recovery pattern. The company's first focus is total joint replacement, with plans to add other procedures if it gains regulatory authorization.

The company framed the product around the shift of surgery out of hospitals. Medical Economics reported that more than 80% of U.S. surgical procedures are now done on an outpatient basis, leaving patients to recover at home during the early period when most complications occur.

Regulatory path and pivotal study

RecovryAI is pursuing FDA authorization under a Class II pathway for patient-facing software as a medical device, according to Medical Economics. The company is running its pivotal clinical study at several sites, including OrthoArizona and Mercy Medical Center in Baltimore. The outlet reported that, if authorized, the FDA decision would establish a new device classification for future patient-facing AI systems in clinical care.

"Health care innovation will not scale without trust," said Scott Walchek, RecovryAI's chief executive and co-founder, as quoted by Medical Economics. "Patient-facing AI inside the care pathway is different. It guides behavior and carries clinical responsibility. In this lane, trust is underwritten by FDA authorization."

STAT placed the designation against the FDA's broader statements on AI. In January, when the agency announced relaxed rules for certain AI products, Commissioner Marty Makary said the FDA is "developing a new regulatory framework for AI," the outlet reported. STAT noted that the wide range of uses for large language models resists simple measures of safety and efficacy, which challenges the agency's long-standing approach to validating devices.

The company said it spent more than two years on product development and clinical evaluation before announcing the designation. It did not give a timeline for submitting a marketing application, and it has not reported results from the pivotal study.